share_log

CV Sciences, Inc. To Announce Third Quarter 2024 Results On November 14, 2024

CV Sciences, Inc. To Announce Third Quarter 2024 Results On November 14, 2024

CV Sciences公司將於2024年11月14日公佈2024年第三季度業績
PR Newswire ·  11/08 09:00

SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the third quarter ended September 30, 2024, before the stock market opens on Thursday, November 14, 2024. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.

聖地亞哥,2024年11月8日/美通社/ - CV Sciences,Inc。 (OTCQB:CVSI) (以下簡稱"公司","CV Sciences","我們","我們"或"我們"),這是一家專門從事大麻提取物和其他經過證實、科學支持的天然成分和產品的領先消費者健康公司,今天宣佈,公司將在2024年9月30日結束的第三季度財務業績之前,在2024年11月14日星期四美國股市開盤前公佈財務業績。該公司將於當天太平洋時間上午7:00(東部時間上午10:00)與投資社區舉行電話會議。

The webcast of the conference call will be available on the Investor Relations section of the Company's website at or directly at . The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.

電話會議的網絡廣播將在公司網站的投資者關係部門 或者 直接鏈接 上提供。網絡廣播將存檔約30天。有興趣參加電話會議的投資者也可以撥打(877) 407-0784(美國)或國際來電可以撥打(201) 689-8560。請在開始時間前15分鐘撥打電話會議號碼,因爲電話會議需求較高。

A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, November 21, 2024, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13749925.

電話重播將在通話結束後約兩小時內提供,可通過撥打(844) 512-2921(美國)或(412) 317-6671(國際)並輸入確認代碼13749925來自2024年11月21日星期四之前提供。

About CV Sciences, Inc.

關於CV Sciences,Inc。

CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company's Cultured Foods brand provides a variety of 100% plant-based food products. Committed to crafting nutritious and flavorful alternatives, Cultured Foods caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. The Company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics. Additional information is available from OTCMarkets.com or by visiting .

CV Sciences,Inc。(OTCQB:CVSI)是一家專門從事保健品和植物性食品的消費者健康公司。該公司的大麻提取物和其他經證實、科學支持的天然成分和產品在美國部分零售位置銷售,並且是自然產品市場中大麻提取物的暢銷品牌,根據SPINS提供的綜合數據和對自然、有機和特殊產品行業的見解。+PlusCBD產品是基於人類臨床研究數據支持在健康人群中的產品效益的科學承諾,此外,還有三份刊登在PubMed.gov的臨床病例研究。+PlusCBD是第一個投資於獲得自行確認的安全(GRAS)地位所需科學證據的大麻提取物補充品牌。該公司的Cultured Foods品牌提供多種100%植物性食品產品。致力於打造營養豐富和口感上佳的替代品,Cultured Foods面向尋求健康且滿足口腹的素食主義者、無麩質或半素食主義者的個人提供選擇。此外,該公司擁有Elevated Softgels,領先的膠囊軟膠囊和滴劑製造商,供補充品和營養行業使用。CV Sciences,Inc。在加利福尼亞州聖地亞哥、科羅拉多州大章克申和波蘭華沙設有主要辦公室和設施。該公司還運營一個專注於開發和商業化基於CBD的新穎治療藥物的藥物開發計劃。更多信息可從OTCMarkets.com獲取或訪問。

FORWARD-LOOKING DISCLAIMER

前瞻性免責聲明

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.

本新聞稿可能包含某些前瞻性聲明和信息,依據1933年證券法第27A條和1934年證券交易法第21E條的定義,並受到這些條款設立的安全港的約束。本材料包含關於預期未來事件和/或財務業績的聲明,具有前瞻性並受到風險和不確定性的影響。這種前瞻性聲明在定義上涉及風險和不確定性。CV Sciences不承擔公開更新任何前瞻性聲明的義務,除非適用法律要求。因此,投資者不應過度依賴此類前瞻性聲明。

CONTACT INFORMATION:
[email protected]

聯繫方式:
[email protected]

SOURCE CV Sciences, Inc.

來源:CV Sciences, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力人士
9k+
9k+

Digital Media
數字媒體

Outlets
Outlets
270k+
270k+

Journalists
記者

Opted In
Opted In
GET STARTED
開始使用
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論